Hematology AdvisorCHIP Significantly Associated with Heart Failure

Non-DNMT3A CHIP carriers face double the heart failure risk of the general population, per a JAMA Cardiology study of 417,616 UK Biobank participants over 11.8 years. Among CHIP carriers diagnosed with incident HF, non-DNMT3A subtypes drove the strongest signal at 4.1% incidence versus 1.7% in non-CHIP patients.

🔬 Clinical Considerations

• Non-DNMT3A CHIP subtypes (TET2, ASXL1, JAK2, spliceosome) carry significantly elevated HF risk beyond DNMT3A, the most common subtype
• 28% of the non-DNMT3A/HF association is mediated through CAD, atrial fibrillation, T2DM, and CKD, implicating systemic inflammatory pathways
• DNMT3A CHIP showed only nominal HF association, suggesting gene-specific risk stratification is now clinically warranted
• Hematologic monitoring of CHIP patients must now incorporate cardiovascular surveillance as a standard care component

🎯 Action Items

• Refer non-DNMT3A CHIP patients to cardiology for baseline HF risk assessment
• Screen CHIP patients for CAD, atrial fibrillation, T2DM, and CKD at diagnosis
• Document CHIP subtype in patient records to guide cardiovascular risk stratification
• Counsel patients that non-DNMT3A CHIP carries measurable heart failure risk

More in Heart Failure